베타락탐 및 베타 락타마아제 저해제 시장 : 약제 클래스별, 질환별, 투여 경로별, 유통 채널별, 최종사용자별, 약제 유형별 - 세계 예측(2025-2030년)

The Beta Lactam & Beta Lactamase Inhibitors Market was valued at USD 26.33 billion in 2023, expected to reach USD 27.33 billion in 2024, and is projected to grow at a CAGR of 4.58%, to USD 36.02 billion by 2030.

The Beta Lactam & Beta Lactamase Inhibitors market is defined by its focus on antibiotics that include both beta lactam antibiotics and beta lactamase inhibitors, essential in combating bacterial infections by targeting and neutralizing the enzymes that confer bacterial resistance. The necessity of these compounds is underscored by the ongoing global challenge posed by antibiotic-resistant bacteria, driving demand in medical and pharmaceutical fields for their application in treating a wide array of bacterial infections. The end-use scope spans hospitals, clinics, and homecare settings, with the majority of demand emerging from regions with advanced healthcare infrastructure. Key growth factors influencing this market include increasing incidence of antibiotic-resistant infections, rising healthcare expenditure, and continuous R&D into novel drug formulations and combinations that enhance efficacy. There are opportunities in the expansion of affordable healthcare services and governmental initiatives to curb antibiotic resistance, as well as the adoption of advanced biotechnology in drug development. However, market growth may be challenged by stringent regulatory frameworks, high costs associated with drug development, and the potential side effects of antibiotics, deterring widespread adoption. The best areas for innovation include developing next-generation beta lactam drugs with broad-spectrum activity and minimal side effects, as well as exploring synergistic combinations that improve treatment efficiency. Investment in diagnostic tools for early detection of resistant strains can also drive market demand. Moreover, fostering collaborative research between pharmaceutical companies and research institutes can enhance insights into bacterial resistance, thus leading to groundbreaking solutions. The market's nature is dynamic, characterized by rapid advancements and a high degree of competition, requiring stakeholders to stay ahead with continuous innovation and strategic planning in product development and market penetration strategies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Lactam & Beta Lactamase Inhibitors Market

The Beta Lactam & Beta Lactamase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of bacterial infections globally
  • Government initiatives and programs to combat antibiotic resistance
  • Rising awareness among healthcare professionals and patients about the benefits of combination antibiotic therapies
• Market Restraints
  • Stringent regulatory requirements and the lengthy approval process for new drugs
• Market Opportunities
  • Development of novel beta-lactamase inhibitors in combination with beta lactam antibiotics
  • Sustainable manufacturing practices to reduce the environmental impact of antibiotic production
• Market Challenges
  • Production complexities associated with beta lactam & beta lactamase inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Beta Lactam & Beta Lactamase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Lactam & Beta Lactamase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Lactam & Beta Lactamase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Lactam & Beta Lactamase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Lactam & Beta Lactamase Inhibitors Market

A detailed market share analysis in the Beta Lactam & Beta Lactamase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Lactam & Beta Lactamase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Lactam & Beta Lactamase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Lactam & Beta Lactamase Inhibitors Market

A strategic analysis of the Beta Lactam & Beta Lactamase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Lactam & Beta Lactamase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Centrient Pharmaceuticals Netherlands B.V., Cipla Ltd., Creative Diagnostics, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Marubeni Corporation, Melinta Therapeutics, LLC, Merck KGaA, Novartis AG, Pfizer Inc., Protech Telelinks, Qpex Biopharma, Inc. by Shionogi Inc., Sanofi SA, SciClone Pharmaceuticals (Holdings) Limited, Sumitomo Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., TOKU-E, Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Beta Lactam & Beta Lactamase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Carbapenem, Cephalosporins, Monobactam, and Penicillin.
• Based on Disease, market is studied across Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI), Nosocomial Pneumonia, Respiratory Infection, Skin Infection, and Urinary Tract Infection (excluding cUTI).
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on Distribution Channels, market is studied across Hospital Pharmacies and Retail Pharmacies.
• Based on End User, market is studied across Clinics, Hospitals, and Specialty Centers.
• Based on Drug Type, market is studied across Over the Counter and Prescribed.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of bacterial infections globally
    • 5.1.1.2. Government initiatives and programs to combat antibiotic resistance
    • 5.1.1.3. Rising awareness among healthcare professionals and patients about the benefits of combination antibiotic therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory requirements and the lengthy approval process for new drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel beta-lactamase inhibitors in combination with beta lactam antibiotics
    • 5.1.3.2. Sustainable manufacturing practices to reduce the environmental impact of antibiotic production
  • 5.1.4. Challenges
    • 5.1.4.1. Production complexities associated with beta lactam & beta lactamase inhibitors
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Innovative strategies to drive growth and effectiveness in the diverse classes of beta lactam & beta lactamase inhibitors
  • 5.2.2. End User: Evolving global market of beta-lactam & beta-lactamase inhibitors: catering to hospitals, and specialty centers with innovative solutions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

• 6.1. Introduction
• 6.2. Carbapenem
• 6.3. Cephalosporins
• 6.4. Monobactam
• 6.5. Penicillin

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Disease

• 7.1. Introduction
• 7.2. Blood Stream Infection
• 7.3. Complicated Intra-Abdominal Infections (cIAI)
• 7.4. Complicated Urinary Tract Infection (cUTI)
• 7.5. Nosocomial Pneumonia
• 7.6. Respiratory Infection
• 7.7. Skin Infection
• 7.8. Urinary Tract Infection (excluding cUTI)

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Distribution Channels

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Retail Pharmacies

10. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Hospitals
• 10.4. Specialty Centers

11. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Type

• 11.1. Introduction
• 11.2. Over the Counter
• 11.3. Prescribed

12. Americas Beta Lactam & Beta Lactamase Inhibitors Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Beta Lactam & Beta Lactamase Inhibitors Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Beta Lactam & Beta Lactamase Inhibitors Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Qpex Biopharma receives USD 10 million BARDA award to advance xeruborbactam development in fight against drug-resistant bacteria
  • 15.3.2. European Commission approves Pfizer's EMBLAVEO for multidrug-resistant infections
  • 15.3.3. Venatorx Pharmaceuticals collaborates with Menarini Group to commercialize cefepime-taniborbactam
  • 15.3.4. Melinta Therapeutics partners with BARDA to develop pediatric antibiotic formulations
  • 15.3.5. Marubeni Corporation collaborates with Fobeni Healthcom and Meiji Seika for clinical trial of innovative B-lactamase inhibitor nacubactam
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca plc
• 3. Aurobindo Pharma Limited
• 4. Bio-Rad Laboratories, Inc.
• 5. Bristol-Myers Squibb Company
• 6. Centrient Pharmaceuticals Netherlands B.V.
• 7. Cipla Ltd.
• 8. Creative Diagnostics
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline PLC
• 11. Marubeni Corporation
• 12. Melinta Therapeutics, LLC
• 13. Merck KGaA
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Protech Telelinks
• 17. Qpex Biopharma, Inc. by Shionogi Inc.
• 18. Sanofi SA
• 19. SciClone Pharmaceuticals (Holdings) Limited
• 20. Sumitomo Pharma Co., Ltd.
• 21. Teva Pharmaceutical Industries Ltd.
• 22. Thermo Fisher Scientific Inc.
• 23. TOKU-E
• 24. Venatorx Pharmaceuticals, Inc.
• 25. Viatris Inc.
• 26. Zai Lab Limited